The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

German pharmaceutical giant Merck has completed a €3 billion ($3.5 billion) takeover of US biopharmaceutical company ...

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 ...

A little over two months after it was announced, Germany-based life sciences firm Merck KGaA said Tuesday that it has ...

SpringWorks Therapeutics (SWTX) ... Merck will pay $47 per share in cash for SpringWorks, representing an equity value of about $3.9 billion or an enterprise value of $3.4 billion, ...

After months of discussion, Germany’s Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a deal with an equity value of nearly $4 billion.

Summary. Merck KGaA agreed to acquire SpringWorks Therapeutics for $47 per share in cash or for $3.9 billion; the acquisition brings in drugs of OGSIVEO and GOMEKLI to big pharma's pipeline.

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said.. An announcement may come as soon as Monday, the people said, asking not to be ...

SpringWorks Therapeutics Inc . (NASDAQ: SWTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and cancer, has been at the center of significant ...